- Home
- OTLY vs BCYC Comparison
OTLY vs BCYC Comparison
Compare OTLY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLY | BCYC |
|---|---|---|
| Founded | 1994 | 2009 |
| Country | Sweden | United Kingdom |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.1M | 360.7M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | OTLY | BCYC |
|---|---|---|
| Price | $9.91 | $4.46 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $15.50 | $14.00 |
| AVG Volume (30 Days) | 49.4K | ★ 441.2K |
| Earning Date | 04-29-2026 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | $37.20 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.35 | $4.30 |
| 52 Week High | $18.84 | $9.69 |
Technical Indicators
Market Signals| Indicator | OTLY | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 38.05 | 31.88 |
| Support Level | N/A | N/A |
| Resistance Level | $12.58 | $7.71 |
| Average True Range (ATR) | 0.53 | 0.29 |
| MACD | -0.10 | -0.06 |
| Stochastic Oscillator | 13.55 | 13.97 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.